Telix Pharmaceuticals Ltd (TLX) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Telix Reports US$186M Q1 Revenue, Up 62% YOY

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate PR Newswire MELBOURNE...

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden PR Newswire MELBOURNE, Australia, April...

Telix Announces Cardinal Health for Gozellix Commercial Distribution

MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Anne Whitaker Appointed as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

MELBOURNE, Australia, April 02, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ:...

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®

BURNABY, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Telix ARTMS, Inc. (ARTMS), a global leader in...

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America PR...

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix...

Telix Adds Lead-212 Isotope Production Capability

Telix Adds Lead-212 Isotope Production Capability PR Newswire MELBOURNE, Australia and INDIANAPOLIS, March 13...